Survival outcomes and duration of response. MRD-negative CR duration is shown for 16 patients achieving MRD-negative CR with CDAR (A), and blood MRD-negative duration is shown for 17 patients becoming blood MRD-negative (B). OS and PFS are shown for all 20 patients (C), and OS after progression is shown for 8 patients who progressed (D). PFS (E) and OS (F) are shown for 5 patients with a TP53 mutation vs 14 patients without a TP53 mutation.